Immunotherapy and Immune Responses

An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancer.

This paper develops an IL6/1 fusokine that enhances T cell survival and anti-tumor response in a preclinical ovarian cancer model.

Type 1-polarized DC immunotherapeutic contains heterogeneous populations with IL-12p70 production restricted to a rare subset

The paper identifies heterogeneous subpopulations within Type 1-polarized dendritic cells (DC1) and shows that IL-12p70 production is restricted to a rare subset, with implications for clinical variability.

Feeder-free generation of functional dendritic cells from human pluripotent stem cells

This study develops a feeder-free method to generate functional human dendritic cells from pluripotent stem cells, outperforming monocyte-derived dendritic cells in antigen presentation and T cell activation.

Harnessing Human Immune Organoid model for Systemic and Comparative Analysis of Clinically Vaccine Adjuvants

This study evaluates clinically relevant vaccine adjuvants using a human immune organoid model, identifying AddaSO3 as consistently effective across early and prolonged immune response phases.

Validation of DoriVac (DNA origami vaccine) efficacy in a metastatic melanoma model

This study validates DoriVac, a DNA origami vaccine, as an effective treatment for metastatic melanoma in mouse models, showing reduced tumor nodules and enhanced immune activation when combined with PD-L1 blockade.

R8-Stabilized Multi-Epitope mRNA Vaccine Triggers Potent Intratumoral T Cell Infiltration and Suppresses Breast Cancer Progression.

A Multi-Omics Computational Pipeline for Systematic Discovery of Retired Self-Antigens as Cancer Vaccine Targets

The paper introduces RADAR, a multi-omics pipeline to identify retired antigens as cancer vaccine targets, validating known targets and discovering novel candidates.

Inhalable Polymeric Nanoparticle Vaccine for Lysosome-targeting Co-delivery of Antigen and Adjuvant with Enhanced Immunoprotection

This paper develops an inhalable nanoparticle vaccine that co-delivers antigen and adjuvant to lysosomes, enhancing immune protection against bacterial pneumonia.

Poly(allylamine)/tripolyphosphate nanocomplex coacervate as a NLRP3-dependent systemic adjuvant for vaccine development

This paper evaluates poly(allylamine)/tripolyphosphate nanocomplex coacervates as a safe systemic adjuvant that activates the NLRP3 inflammasome to enhance Th1-dependent immune responses.

Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA(R)) Platform Elicits Enhanced Humoral and Cellular Immune Responses

This study evaluates the ALTA(R) platform for vaccine formulation, showing enhanced humoral and cellular immune responses compared to liquid adjuvanted vaccines.

Engineering age-adaptive mRNA lipid nanoparticle cancer vaccines via reprogramming systemic gene expression

This paper identifies age-related impairment in systemic mRNA translation as a barrier to mRNA vaccine efficacy and develops an LNP formulation to restore transgene expression and T cell immunity in aged hosts.

Overlapping MHC class I/II Epitopes Program cDC1-like Differentiation of Monocyte-Derived Dendritic Cells via mTORC1 Signaling Inhibition

The paper shows that overlapping MHC class I/II epitopes promote cDC1-like differentiation of moDC through mTORC1 inhibition, enhancing type 1 immunity.

Successful dendritic cell vaccines require lasting in-situ TNF α secretion to license antitumor CD8 + T cell cytotoxicity

The paper identifies that TNFα secretion by tumor-infiltrating myeloid DCs is critical for CD8 T cell cytotoxicity, and shows that DC vaccines lose this function, limiting their efficacy.

Cytokine-bearing Bacterial Outer Membrane Vesicles with Empowered Efficacy in Intratumoral Immunotherapy

This study engineers bacterial outer membrane vesicles with cytokines to enhance antitumor efficacy in intratumoral immunotherapy, achieving tumor eradication in over 95% of mice.

DAMP-inducing Peptide Nanofibers and PAMP Combination Adjuvants Boost Functional Lung Tissue-resident Memory CD4+ T Cell Responses

This study shows that combining DAMP-inducing peptide nanofibers with a PAMP enhances lung-resident memory CD4+ T cell responses, improving protection against TB and respiratory diseases.

A genome-wide CRISPR Screening identifies targets that drive Tolerogenic Dendritic Cells

This study uses CRISPR screening to identify molecular targets that drive the function of tolerogenic dendritic cells, revealing CD86 and UBE2L6 as key regulators of immune tolerance.

Histone methyltransferase DOT1L differentially affects the development of dendritic cell subsets

This study shows that DOT1L influences dendritic cell subset development and antigen presentation by modulating histone H3K79 methylation.

In situ generated vaccine-like pyroptosome for personalized cancer immunotherapy

This paper develops a nanoadjuvant that induces localized pyroptosis to generate vaccine-like pyroptosomes, enhancing anti-tumor immunity while avoiding systemic toxicity.

Exploiting HLA-II Promiscuity via Peptide Terminal Overhang Recognition for Pan-Allelic and Tumor-Selective AML Immunotherapy

This paper identifies an MPO-derived epitope promiscuously presented by HLA-II molecules and develops a pan-allelic antibody that selectively targets AML cells while sparing normal myeloid cells.

Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

This study shows that membrane-localized xenoantigens enhance CD4+ T cell responses and improve anti-PD-1 therapy efficacy in pre-immunized mice, using OVA and VZV gE antigens.

Analysis of tumor-derived and cross-presented peptide antigens defines improved immunotherapeutic strategies

The paper identifies cross-presented tumor antigens in glioblastoma and shows that targeting these antigens with mRNA vaccines improves anti-tumor immunity.

Mutations outside the MR1 antigen binding groove differentially inhibit presentation of exogenous antigens

This study shows that mutations in MR1 outside the antigen binding groove differentially affect exogenous antigen presentation by altering B2M association.

Tumors Located in the Brain Impair the Frequency and Phenotype of Dendritic Cells in Blood and Tumor

This paper identifies systemic reductions in dendritic cell (DC) numbers and activation markers in brain tumor patients, with brain tumors directly contributing to DC defects, and highlights corticosteroid use as a confounding factor.

B cells maintain the homeostasis of splenic marginal zone antigen-presenting cells to promote the anti-viral CD8+ T cell response

This study shows B cells sustain Langerin+ cDC1s via LTβ and MMMs to support anti-viral CD8+ T cell responses during MCMV infection.

Tumor-derived Extracellular Vesicles Induce ER Stress to Drive Tolerogenic Dendritic Cell Development in the Tumor Microenvironment

This paper shows tumor-derived extracellular vesicles induce ER stress in dendritic cells, promoting tolerogenic DCs that suppress antitumor immunity, and identifies PPAR-α inhibition as a potential therapeutic strategy.

Oxidative Stress-Induced Immunogenic Cell Death Enhances Whole-Cell Vaccine Efficacy in a Syngeneic Pancreatic Cancer Model

This study shows that inducing oxidative stress in pancreatic cancer cells creates an effective whole-cell vaccine that enhances anti-tumor immunity and synergizes with PD-1 blockade.

Spatial immune hubs defined by conserved activated dendritic cells are remodeled by immunotherapy

The paper constructs an integrated atlas of tumor-infiltrating dendritic cells across species and immunotherapy conditions, revealing conserved activation states and spatial reorganization in response to therapy.

Ripk1 Deficiency or K376R Mutation in Dendritic Cells Promotes Potent Antitumor Immunity

This study shows that RIPK1 deficiency or K376R mutation in dendritic cells enhances antitumor immunity by improving antigen presentation and T cell activation.

Non-cytolytic re-engineering of a viral vaccine vector enables durable effector-memory T cell immunity by reinforcing type I IFN induction

This paper re-engineers a cytolytic viral vector to be non-cytolytic, enhancing CD8 T cell immunity through reinforced type I IFN signaling.

Antigen accumulation in the B cell follicle is impaired in aged mice

This study shows that aged mice have reduced accumulation of small antigens in B cell follicles, potentially affecting vaccine responses.